ARWR SEC filings (2026)
CIK 879407 · Pharmaceutical Preparations (SIC 2834) · incorporated in DE · fiscal year ends in September
1,351 filings on EDGAR since 1998 · 22 annual, 66 quarterly, 264 current · financial statements · earnings
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by what they covered, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
August 2026
- Aug 18Insider salePERRY MICHAEL S (Director) sold 11,600 shares for $1.0M at $87.30
- Aug 18Insider saleOLUKOTUN ADEOYE Y (Director) sold 2,000 shares for $174K at $86.96
- Aug 4EarningsEarnings release — EPS −$1.36 vs −$1.23 est. (−10.6%); revenue $75.3M (+171% y/y) 3.0%
- Aug 4ReportQuarterly report, Q3 2026 — revenue $75.3M (+171% y/y), net income −$194.3M, EPS −$1.36
June 2026
- Jun 168-K8-K · Directors or officers; compensation
May 2026
April 2026
March 2026
- Mar 208-K8-K · Shareholder vote results
- Mar 5Insider saleHamilton James C (Chief Medical Officer) sold 10,000 shares for $642K at $64.19 under a 10b5-1 plan
February 2026
January 2026
- Jan 27ProxyProxy · Annual report to shareholders
- Jan 27ProxyProxy · Additional proxy materials
- Jan 27ProxyProxy · Proxy statement
- Jan 128-K8-K · Material definitive agreement; New financial obligation
- Jan 98-K8-K · Material definitive agreement; Other events
- Jan 68-K8-K · Regulation FD disclosure; Other events
- Jan 5Insider saleO'Brien Patrick (COO) sold 49,493 shares for $3.1M at $61.12–$68.00 under a 10b5-1 plan
- Jan 5Insider saleHamilton James C (Chief Medical Officer) sold 40,164 shares for $2.5M at $61.24–$68.00 under a 10b5-1 plan
- Jan 2Insider saleAnzalone Christopher Richard (Chief Executive Officer · Director) sold 13,187 shares for $872K at $65.88–$66.39 under a 10b5-1 plan
November 2025
- Nov 25EarningsEarnings release — EPS −$0.18 vs $0.12 est. (−250.0%); revenue $256.5M 23.3%
- Nov 25ReportAnnual report, FY2025 — revenue $829.4M (+23258% y/y), net income −$1.6M, EPS −$0.01
- Nov 188-K8-K · Other events
October 2025
- Oct 10ReportAnnual report, amended
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $10.3M in 9 sales and bought nothing on the open market; 6 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Aug 18, 2026Form 4 | PERRY MICHAEL SDirectorSold · $1.0M · 11,600 sh |
| Aug 18, 2026Form 4 | OLUKOTUN ADEOYE YDirectorSold · $174K · 2,000 sh |
| May 12, 2026Form 4 | Lu HongboDirectorSold · $228K · 2,970 sh · 10b5-1 |
| Apr 23, 2026Form 4 | Hamilton James CChief Medical OfficerSold · $750K · 10,000 sh · 10b5-1 |
| Apr 22, 2026Form 4 | Apel Daniel JosephChief Financial OfficerSold · $934K · 13,095 sh · 10b5-1 |
| Mar 5, 2026Form 4 | Hamilton James CChief Medical OfficerSold · $642K · 10,000 sh · 10b5-1 |
| Jan 5, 2026Form 4 | O'Brien PatrickCOOSold · $3.1M · 49,493 sh · 10b5-1 |
| Jan 5, 2026Form 4 | Hamilton James CChief Medical OfficerSold · $2.5M · 40,164 sh · 10b5-1 |
| Jan 2, 2026Form 4 | Anzalone Christopher RichardChief Executive Officer · DirectorSold · $872K · 13,187 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 6 transactions
| Date | Insider |
|---|---|
| Jun 15, 2026Form 4 | Cohen Matthew GregoryDirectorAward · $0 · 11,882 sh |
| Jan 6, 2026Form 4 | O'Brien PatrickCOOAward · $0 · 75,000 sh |
| Jan 6, 2026Form 4 | Hamilton James CChief Medical OfficerAward · $0 · 75,000 sh |
| Jan 6, 2026Form 4 | Apel Daniel JosephChief Financial OfficerAward · $0 · 75,000 sh |
| Jan 6, 2026Form 4 | O'Brien PatrickCOOGift · $0 · 2,500 sh |
| Dec 31, 2025Form 4 | O'Brien PatrickCOOGift · $0 · 2,800 sh · 10b5-1 |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K is described by its items. A form opens the document on EDGAR, or the filing’s index where it furnishes exhibits (an earnings release is the 8-K’s Exhibit 99.1).
2026 · 14 filings
| Filed | What it is |
|---|---|
| Aug 4, 20268-K | Earnings release — EPS −$1.36 vs −$1.23 est. (−10.6%); revenue $75.3M (+171% y/y) 3.0% |
| Aug 4, 202610-Q | Quarterly report, Q3 2026 — revenue $75.3M (+171% y/y), net income −$194.3M, EPS −$1.36 |
| Jun 16, 20268-K | Directors or officers; compensation |
| May 7, 202610-Q | Quarterly report, Q2 2026 — revenue $73.7M (−86% y/y), net income −$132.7M, EPS −$0.93 |
| May 7, 20268-K | Earnings release — EPS −$0.93 vs −$1.18 est. (+21.2%); revenue $73.7M (−86% y/y) 6.7% |
| Mar 20, 20268-K | Shareholder vote results |
| Feb 5, 202610-Q | Quarterly report, Q1 FY2026 — revenue $264.0M (+10461% y/y), net income $30.8M, EPS $0.22 |
| Feb 5, 20268-K | Earnings release — EPS $0.22 vs $0.60 est. (−63.3%); revenue $264.0M (+10461% y/y) 0.2% |
| Jan 27, 2026ARS | Annual report to shareholders |
| Jan 27, 2026DEFA14A | Additional proxy materials |
| Jan 27, 2026DEF 14A | Proxy statement |
| Jan 12, 20268-K | Material definitive agreement; New financial obligation |
| Jan 9, 20268-K | Material definitive agreement; Other events |
| Jan 6, 20268-K | Regulation FD disclosure; Other events |
2025 · 20 filings
| Filed | What it is |
|---|---|
| Nov 25, 202510-K | Annual report, FY2025 — revenue $829.4M (+23258% y/y), net income −$1.6M, EPS −$0.01 |
| Nov 25, 20258-K | Earnings release — EPS −$0.18 vs $0.12 est. (−250.0%); revenue $256.5M 23.3% |
| Nov 18, 20258-K | Other events |
| Oct 10, 202510-K/A | Annual report, amended |
| Sep 12, 20258-K | Other events |
| Sep 11, 20258-K | Other events |
| Sep 2, 20258-K | Material definitive agreement |
| Aug 7, 20258-K | Results of operations |
| Aug 7, 202510-Q | Quarterly report, Q3 2025 — revenue $27.8M, net income −$175.2M, EPS −$1.26 |
| May 12, 20258-K | Results of operations |
| May 12, 202510-Q | Quarterly report, Q2 2025 — revenue $542.7M, net income $370.4M, EPS $2.75 |
| Apr 15, 20258-K | Directors or officers; compensation |
| Mar 19, 20258-K | Shareholder vote results |
| Feb 10, 20258-K | Results of operations |
| Feb 10, 202510-Q | Quarterly report, Q1 FY2025 — revenue $2.5M (−30% y/y), net income −$173.1M, EPS −$1.39 |
| Feb 7, 2025DEFA14A | Additional proxy materials |
| Feb 7, 20258-K | Directors or officers; compensation |
| Jan 29, 2025ARS | Annual report to shareholders |
| Jan 29, 2025DEFA14A | Additional proxy materials |
| Jan 29, 2025DEF 14A | Proxy statement |
2024 · 18 filings
| Filed | What it is |
|---|---|
| Dec 18, 20248-K | Directors or officers; compensation |
| Nov 26, 20248-K | Results of operations |
| Nov 26, 202410-K | Annual report, FY2024 — revenue $3.6M (−99% y/y), net income −$599.5M, EPS −$5.00 |
| Aug 8, 20248-K | Results of operations |
| Aug 8, 202410-Q | Quarterly report, Q3 2024 — revenue $0 (−100% y/y), net income −$170.8M, EPS −$1.38 |
| May 9, 20248-K | Results of operations |
| May 9, 202410-Q | Quarterly report, Q2 2024 — revenue $0 (−100% y/y), net income −$125.3M, EPS −$1.02 |
| Mar 19, 20248-K | Shareholder vote results |
| Mar 18, 20248-K/A | Directors or officers; compensation |
| Feb 27, 2024DEFA14A | Additional proxy materials |
| Feb 22, 20248-K | Directors or officers; compensation |
| Feb 6, 202410-Q | Quarterly report, Q1 FY2024 — revenue $3.6M (−94% y/y), net income −$132.9M, EPS −$1.24 |
| Feb 6, 20248-K | Results of operations |
| Jan 29, 2024ARS | Annual report to shareholders |
| Jan 26, 2024DEFA14A | Additional proxy materials |
| Jan 26, 2024DEF 14A | Proxy statement |
| Jan 22, 20248-K | Directors or officers; compensation |
| Jan 4, 20248-K | Material definitive agreement |
2023 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 29, 202310-K | Annual report, FY2023 — revenue $240.7M (−1% y/y), net income −$205.3M, EPS −$1.92 |
| Aug 7, 202310-Q | Quarterly report, Q3 2023 — revenue $15.8M (−51% y/y), net income −$102.9M, EPS −$0.96 |
| May 2, 202310-Q | Quarterly report, Q2 2023 — revenue $146.3M (−4% y/y), net income $48.7M, EPS $0.45 |
| Feb 6, 202310-Q | Quarterly report, Q1 FY2023 — revenue $62.5M (+128% y/y), net income −$41.3M, EPS −$0.39 |
| Jan 30, 2023DEF 14A | Proxy statement |
| Jan 20, 2023PRE 14A | Preliminary proxy statement |
10 current reports (8-K) not listed; the year is on EDGAR.
2022 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 28, 202210-K | Annual report, FY2022 — revenue $243.2M (+76% y/y), net income −$176.1M, EPS −$1.67 |
| Aug 4, 202210-Q | Quarterly report, Q3 2022 — revenue $32.4M (−29% y/y), net income −$72.0M, EPS −$0.68 |
| May 10, 202210-Q | Quarterly report, Q2 2022 — revenue $151.8M (+363% y/y), net income $44.4M, EPS $0.41 |
| Mar 9, 2022DEFA14A | Additional proxy materials |
| Feb 2, 202210-Q | Quarterly report, Q1 FY2022 — revenue $27.4M (+29% y/y), net income −$62.9M, EPS −$0.60 |
| Jan 26, 2022DEF 14A | Proxy statement |
11 current reports (8-K) not listed; the year is on EDGAR.
2021 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 22, 202110-K | Annual report, FY2021 — revenue $138.3M (+57% y/y), net income −$140.8M, EPS −$1.36 |
| Aug 5, 202110-Q | Quarterly report, Q3 2021 — revenue $45.9M (+68% y/y), net income −$29.9M, EPS −$0.29 |
| May 4, 202110-Q | Quarterly report, Q2 2021 — revenue $32.8M (+39% y/y), net income −$26.8M, EPS −$0.26 |
| Feb 4, 202110-Q | Quarterly report, Q1 FY2021 — revenue $21.3M (−28% y/y), net income −$20.7M, EPS −$0.20 |
| Jan 28, 2021DEF 14A | Proxy statement |
10 current reports (8-K) not listed; the year is on EDGAR.
2020 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 23, 202010-K | Annual report, FY2020 — revenue $88.0M (−48% y/y), net income −$84.6M, EPS −$0.84 |
| Aug 5, 202010-Q | Quarterly report, Q3 2020 — revenue $27.4M (−36% y/y), net income −$13.6M, EPS −$0.13 |
| May 7, 202010-Q | Quarterly report, Q2 2020 — revenue $23.5M (−51% y/y), net income −$19.8M, EPS −$0.20 |
| Feb 5, 202010-Q | Quarterly report, Q1 FY2020 — revenue $29.5M (−15% y/y), net income −$2.7M, EPS −$0.03 |
| Jan 28, 2020DEF 14A | Proxy statement |
| Jan 14, 2020PRE 14A | Preliminary proxy statement |
8 current reports (8-K) not listed; the year is on EDGAR.
2019 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 25, 201910-K | Annual report, FY2019 — revenue $168.8M (+946% y/y), net income $68.0M, EPS $0.69 |
| Aug 5, 201910-Q | Quarterly report, Q3 2019 — revenue $42.7M (+5770% y/y), net income $20.3M, EPS $0.21 |
| May 8, 201910-Q | Quarterly report, Q2 2019 — revenue $48.1M (+7306% y/y), net income $23.9M, EPS $0.24 |
| Feb 7, 201910-Q | Quarterly report, Q1 FY2019 — revenue $34.7M (+887% y/y), net income $12.0M, EPS $0.13 |
| Jan 25, 2019DEFA14A | Additional proxy materials |
| Jan 25, 2019DEF 14A | Proxy statement |
11 current reports (8-K) not listed; the year is on EDGAR.
2018 · 13 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Dec 11, 201810-K | Annual report, FY2018 — revenue $16.1M (−49% y/y), net income −$54.5M, EPS −$0.65 |
| Aug 7, 201810-Q | Quarterly report, Q3 2018 — revenue $727K (−92% y/y), net income −$15.6M, EPS −$0.18 |
| May 8, 201810-Q | Quarterly report, Q2 2018 — revenue $650K (−93% y/y), net income −$14.9M, EPS −$0.18 |
| Feb 9, 201810-Q | Quarterly report, Q1 FY2018 — revenue $3.5M (−20% y/y), net income −$13.2M, EPS −$0.18 |
| Jan 25, 2018DEFA14A | Additional proxy materials |
| Jan 25, 2018DEF 14A | Proxy statement |
7 current reports (8-K) not listed; the year is on EDGAR.
2017 · 12 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Dec 12, 201710-K | Annual report, FY2017 — revenue $31.4M (+19736% y/y), net income −$34.4M, EPS −$0.47 |
| Aug 3, 201710-Q | Quarterly report, Q3 2017 — revenue $9.3M (+23502% y/y), net income −$5.5M |
| May 3, 201710-Q | Quarterly report, Q2 2017 — revenue $9.0M (+20439% y/y), net income −$6.0M |
| Feb 6, 201710-Q | Quarterly report, Q1 FY2017 — revenue $4.4M (+9878% y/y), net income −$12.1M |
| Feb 1, 2017DEFA14A | Additional proxy materials |
| Feb 1, 2017DEF 14A | Proxy statement |
6 current reports (8-K) not listed; the year is on EDGAR.
2016 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2015 · 12 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2014 · 12 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K
Counted, not listed; the year is on EDGAR.
2013 · 14 filings — 8 × 8-K, 3 × 10-Q, 2 × DEF 14A and 1 other form
Counted, not listed; the year is on EDGAR.
2012 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2011 · 26 filings — 18 × 8-K, 3 × 10-Q, 2 × PRE 14A and 3 other forms
Counted, not listed; the year is on EDGAR.
2010 · 25 filings — 19 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2009 · 30 filings — 19 × 8-K, 3 × 10-Q, 2 × DEF 14A and 5 other forms
Counted, not listed; the year is on EDGAR.
2008 · 30 filings — 21 × 8-K, 3 × 10-Q, 3 × 8-K/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2007 · 25 filings — 16 × 8-K, 3 × 10-Q, 2 × 10-Q/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2006 · 13 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2005 · 11 filings — 11 × 8-K
Counted, not listed; the year is on EDGAR.
2004 · 12 filings — 9 × 8-K, 1 × 8-K/A, 1 × DEF 14A and 1 other form
Counted, not listed; the year is on EDGAR.
2003 · 1 filing — 1 × 8-K
Counted, not listed; the year is on EDGAR.
1999 · 1 filing — 1 × 8-K
Counted, not listed; the year is on EDGAR.
1998 · 1 filing — 1 × 10-Q
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 41 filings — 13 × 4, 9 × 144, 4 × 144/A and 7 other forms
| Filed | What it is |
|---|---|
| Aug 20, 20264 | Insider transaction (Form 4) |
| Aug 20, 20264 | Insider transaction (Form 4) |
| Aug 18, 2026144 | Notice of proposed sale (Form 144) |
| Aug 18, 2026144 | Notice of proposed sale (Form 144) |
| Aug 14, 2026SCHEDULE 13G/A | Other filings |
| Jul 31, 2026SCHEDULE 13G/A | Other filings |
| Jun 17, 20264 | Insider transaction (Form 4) |
| Jun 17, 20263 | Initial insider holdings (Form 3) |
| May 19, 2026144/A | Notice of proposed sale (Form 144), amended |
| May 19, 2026144/A | Notice of proposed sale (Form 144), amended |
| May 19, 2026144/A | Notice of proposed sale (Form 144), amended |
| May 14, 20264 | Insider transaction (Form 4) |
| May 12, 2026144 | Notice of proposed sale (Form 144) |
| May 7, 2026S-8 | Employee stock plan registration |
| May 6, 2026SCHEDULE 13G | Other filings |
| Apr 29, 2026SCHEDULE 13G | Other filings |
| Apr 28, 2026SCHEDULE 13G | Other filings |
| Apr 24, 20264 | Insider transaction (Form 4) |
| Apr 24, 20264 | Insider transaction (Form 4) |
| Apr 23, 2026144 | Notice of proposed sale (Form 144) |
| Apr 22, 2026144 | Notice of proposed sale (Form 144) |
| Mar 26, 2026SCHEDULE 13G/A | Other filings |
| Mar 9, 20264 | Insider transaction (Form 4) |
| Mar 5, 2026144 | Notice of proposed sale (Form 144) |
| Jan 9, 2026424B5 | Prospectus supplement |
The newest 25 of 41 shown; the full year is on EDGAR.
2025 · 77 filings — 36 × 144, 31 × 4, 4 × SCHEDULE 13G/A and 5 other forms
| Filed | What it is |
|---|---|
| Dec 30, 20254 | Insider transaction (Form 4) |
| Dec 30, 20254 | Insider transaction (Form 4) |
| Dec 29, 2025144 | Notice of proposed sale (Form 144) |
| Dec 29, 2025144 | Notice of proposed sale (Form 144) |
| Dec 23, 20254 | Insider transaction (Form 4) |
| Dec 23, 20254 | Insider transaction (Form 4) |
| Dec 23, 20254 | Insider transaction (Form 4) |
| Dec 23, 20254 | Insider transaction (Form 4) |
| Dec 22, 2025144 | Notice of proposed sale (Form 144) |
| Dec 19, 20254 | Insider transaction (Form 4) |
| Dec 19, 2025144 | Notice of proposed sale (Form 144) |
| Dec 19, 2025144 | Notice of proposed sale (Form 144) |
| Dec 19, 2025144 | Notice of proposed sale (Form 144) |
| Dec 19, 2025144 | Notice of proposed sale (Form 144) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 17, 2025144 | Notice of proposed sale (Form 144) |
| Dec 16, 2025144 | Notice of proposed sale (Form 144) |
| Dec 16, 20254 | Insider transaction (Form 4) |
| Dec 15, 2025144 | Notice of proposed sale (Form 144) |
The newest 25 of 77 shown; the full year is on EDGAR.
2024 · 70 filings — 29 × 144, 29 × 4, 5 × SC 13G/A and 7 other forms
| Filed | What it is |
|---|---|
| Dec 30, 20244 | Insider transaction (Form 4) |
| Dec 27, 2024144 | Notice of proposed sale (Form 144) |
| Dec 23, 20244 | Insider transaction (Form 4) |
| Dec 23, 2024144 | Notice of proposed sale (Form 144) |
| Dec 20, 20244 | Insider transaction (Form 4) |
| Dec 20, 20244 | Insider transaction (Form 4) |
| Dec 20, 20244 | Insider transaction (Form 4) |
| Dec 20, 20244 | Insider transaction (Form 4) |
| Dec 20, 20244 | Insider transaction (Form 4) |
| Dec 20, 20244 | Insider transaction (Form 4) |
| Dec 20, 20244 | Insider transaction (Form 4) |
| Dec 20, 2024424B7 | Registration and prospectus |
| Dec 18, 20244 | Insider transaction (Form 4) |
| Dec 18, 20244 | Insider transaction (Form 4) |
| Dec 18, 20244 | Insider transaction (Form 4) |
| Dec 18, 2024144 | Notice of proposed sale (Form 144) |
| Dec 17, 2024144 | Notice of proposed sale (Form 144) |
| Dec 17, 2024144 | Notice of proposed sale (Form 144) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Nov 15, 20245 | Annual insider holdings (Form 5) |
| Nov 14, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Oct 16, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Jul 3, 20244 | Insider transaction (Form 4) |
The newest 25 of 70 shown; the full year is on EDGAR.
2023 · 53 filings — 32 × 4, 10 × 144, 4 × SC 13G/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2022 · 33 filings — 26 × 4, 3 × SC 13G/A, 2 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2021 · 37 filings — 30 × 4, 2 × S-8, 2 × SC 13G/A and 2 other forms
Counted, not listed; the year is on EDGAR.
2020 · 47 filings — 37 × 4, 5 × SC 13G/A, 3 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2019 · 54 filings — 39 × 4, 4 × SC 13G, 3 × 3 and 5 other forms
Counted, not listed; the year is on EDGAR.
2018 · 37 filings — 27 × 4, 2 × 424B5, 2 × SC 13G and 5 other forms
Counted, not listed; the year is on EDGAR.
2017 · 30 filings — 9 × 4, 6 × CORRESP, 4 × SC 13G/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2016 · 42 filings — 18 × 4, 6 × SC 13G/A, 4 × S-3/A and 8 other forms
Counted, not listed; the year is on EDGAR.
2015 · 31 filings — 10 × 4, 5 × SC 13G/A, 4 × SC 13G and 7 other forms
Counted, not listed; the year is on EDGAR.
2014 · 47 filings — 18 × 4, 10 × SC 13G/A, 5 × SC 13G and 11 other forms
Counted, not listed; the year is on EDGAR.
2013 · 42 filings — 18 × 4, 6 × SC 13G, 4 × 4/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2012 · 45 filings — 13 × 4, 6 × CORRESP, 5 × EFFECT and 11 other forms
Counted, not listed; the year is on EDGAR.
2011 · 15 filings — 4 × 4, 4 × S-3, 2 × UPLOAD and 5 other forms
Counted, not listed; the year is on EDGAR.
2010 · 31 filings — 10 × 4, 5 × EFFECT, 4 × 424B3 and 7 other forms
Counted, not listed; the year is on EDGAR.
2009 · 46 filings — 22 × 4, 5 × UPLOAD, 4 × CORRESP and 11 other forms
Counted, not listed; the year is on EDGAR.
2008 · 13 filings — 3 × 424B5, 3 × SC 13G/A, 2 × 3 and 5 other forms
Counted, not listed; the year is on EDGAR.
2007 · 48 filings — 23 × 4, 7 × CORRESP, 4 × 3 and 10 other forms
Counted, not listed; the year is on EDGAR.
2006 · 23 filings — 6 × 4, 2 × 424B3, 2 × CORRESP and 11 other forms
Counted, not listed; the year is on EDGAR.
2005 · 25 filings — 14 × 4, 3 × 10QSB, 2 × 3 and 6 other forms
Counted, not listed; the year is on EDGAR.
2004 · 31 filings — 7 × 3, 7 × 4, 3 × 10QSB and 10 other forms
Counted, not listed; the year is on EDGAR.
2003 · 8 filings — 3 × 10QSB, 1 × 10KSB, 1 × DEF 14C and 3 other forms
Counted, not listed; the year is on EDGAR.
2002 · 6 filings — 3 × 10QSB, 2 × NT 10-Q, 1 × NT 10-K
Counted, not listed; the year is on EDGAR.
2001 · 5 filings — 3 × 10QSB, 1 × 10KSB, 1 × NT 10-Q
Counted, not listed; the year is on EDGAR.
2000 · 7 filings — 3 × 10QSB, 2 × 10KSB, 1 × DEF 14C and 1 other form
Counted, not listed; the year is on EDGAR.
1999 · 3 filings — 1 × 10QSB, 1 × NT 10-Q, 1 × NTN 10Q
Counted, not listed; the year is on EDGAR.
1998 · 4 filings — 2 × 10KSB, 2 × 10QSB
Counted, not listed; the year is on EDGAR.
About this data
Arrowhead Pharmaceuticals Inc. (ARWR) has 1,351 filings on EDGAR going back to 1998: 22 annual reports, 66 quarterly reports and 264 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Nov 25, 2025 for the fiscal year ended Sep 30, 2025. The most recent 8-K, on Aug 4, 2026, covered results of operations. Over the last 13 months insiders sold $10.3M in 9 sales and bought nothing on the open market; 6 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Arrowhead Pharmaceuticals Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read ARWR's latest 10-K?
- ARWR's latest annual report, a 10-K, was filed on Nov 25, 2025 for the fiscal year ended Sep 30, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did ARWR last file an 8-K?
- On Aug 4, 2026: results of operations. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 4, 2026.
- Are ARWR insiders buying or selling?
- Over the last 13 months insiders sold $10.3M in 9 sales and bought nothing on the open market; 6 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: PERRY MICHAEL S (Director) sold 11,600 shares on Aug 18, 2026 for $1.0M. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has ARWR made?
- 1,351 filings are on EDGAR under the registrant records that have been Arrowhead Pharmaceuticals Inc., going back to 1998; 586 of them are insider ownership forms (Forms 3, 4, 5 and 144).